The relevant disclosure is attached

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website : www.fortishealthcare.com November 5, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Earnings Presentation under Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Dear Madam/Sir, Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the ‘Earning Presentation’ for the quarter and half year ended September 30, 2026. The date and time of occurrence of event is Thursday, November 5, 2026 at 06:05 PM (IST). This is for your information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. - A14783 Encl : As stated above FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel :0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q2 FY27 and H1 FY27 November 05, 2026 DISCLAIMER Thispresentationmaynotbecopied,published,distributedortransmitted.Thepresentationhasbeenpreparedsolelybythecompany. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is notan offerorinvitation tobuyorsell anysecurities,norshall part,orall,of this presentationform the basis of,orbe relied onin connection with,any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitationofanoffertobuysecuritiesofthecompanyforsaleintheUnitedStates,Indiaoranyotherjurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only bymeans of an offering document thatmay be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable lawsofthatjurisdiction. Thispresentationcontainsforward-lookingstatementsbasedonthecurrentlyheldbeliefsandassumptionsofthemanagementoftheCompany, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks,uncertaintiesandotherfactors,recipientsofthispresentationarecautionednottoplaceunduerelianceontheseforward-lookingstatements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any personofsuchrevisionorchanges. By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential futureperformanceofthebusinessoftheCompany. Neither the delivery of this presentation nor anyfurther discussions of the Company with any of the recipients shall, under any circumstances, create anyimplicationthattherehasbeennochangeintheaffairsoftheCompanysincethatdate. About Fortis Healthcare National Capital Region ➢ FMRI, Gurugram 37 Healthcare Facilities ➢ FEHI, New Delhi ➢ Shalimar Bagh ➢ Noida 2,210 Himachal Pradesh ➢ Vasant Kunj (O&M) 6,300+ Operational Beds^ ➢ Faridabad ➢ Kangra(O&M) 81 Punjab ➢ Manesar, Gurugram ➢ La Femme GK ➢ Mohali ➢ Def Col 8,400+ Doctors ➢ Ludhiana 1,017 ➢ C-DOC (O&M) ➢ Ludhiana 2 ➢ Greater Noida ➢ Amritsar ➢ Adayu ➢ Jalandhar 9,500+ Nurses# Rajasthan ➢ Jaipur 275 391 West Bengal 29,000+ employees Kolkata (including Agilus) Maharashtra ➢ Anandpur ➢ FHKI & FMC Chhattisgarh ➢ Mulund ➢ Vashi ➢ Raigarh (O&M) 70 ➢ Kalyan Telangana ➢ SL Raheja (O&M) Hyderabad Karnataka 4 JCI Accredited ➢ Lakdi-Ka-Pul(O&M) 271 Bengaluru ➢ L.B. Nagar (O&M) ➢ BG Road ➢ CG Road Tamil Nadu 998 ➢ NagarBhavi Chennai 35 NABH Accredited/ ➢ Rajaji Nagar Certified ➢ Perumbakkam–Sholinganallur (O&M) ➢ Yeshwanthpur ➢ Rajaji Nagar (Suguna) ➢ Kengeri(O&M) Beds Note: ^Including ~1,200 O&M beds 3 ➢ Richmond Road (O&M) # Including trainee nurses AGENDA 1. Performance Highlights • Earnings and Financial Summary – Q2FY27 and H1FY27 2. Performance Review - Hospital Business • Beds Expansion Strategy 3. Performance Review - Diagnostics Business 4. Clinical Excellence at Fortis 5. Appendix Q2FY27 and H1FY27 PERFORMANCE HIGHLIGHTS Q2FY27 SNAPSHOT Consolidated Revenue Consolidated PBT1 Consolidated PAT1 2,735 Crores 429 Crores 317 Crores (11.6% Margin) 17.3% 6.8% 4.0% Net Debt / (Cash)3 Net Debt to EBITDA2,3 2,188 Crores 0.87x vs 0.96x 1. Excluding exceptional items 2. Basis Q2 annualized EBITDA 3. Net Debt as on 30th September 2026 H1FY27 SNAPSHOT Consolidated Revenue Consolidated PBT1 Consolidated PAT1 5,280 Crores 783 Crores 581 Crores (11.0% Margin) 17.4% 5.8% 3.8% Net Debt / (Cash)3 Net Debt to EBITDA2,3 2,188 Crores 0.87x vs 0.96x 1. Excluding exceptional items 2. Basis Q2 annualized EBITDA 3. Net Debt as on 30th September 2026 Recent Key Updates Definitive Agreements to provide Healthcare services to a 400+ Bedded Hospital in Ashok Vihar, Delhi Sep’26: Fortis Healthcare, through its wholly owned subsidiary, entered into definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services at a 400+ bedded super-specialty hospital in Ashok Vihar, New Delhi. Under a 29-year Healthcare Services Agreement, Fortis will provide specified inpatient healthcare services, specialized medical equipment and clinical manpower, while the SLJ Society will own and develop the hospital infrastructure. The ~3.1 acre facility is expected to commence operations in 3–4 years, subject to necessary approvals, with development planned in phases. Fortis Acquires 110-Bedded Suguna Hospital in Bengaluru Oct’26: Fortis Healthcare, through its wholly owned subsidiary, acquired Suguna Hospital, a 110 bedded facility in Rajajinagar, North-West Bengaluru, in an all cash deal for ~INR 277 crores. The transaction includes the hospital’s entire business operations (through slump sale), land and building. The facility located in a dense affluent catchment has the potential to expand to ~150 beds and will strengthen Fortis’ presence in Bengaluru with ~1,000 operational beds (including O&M) Q2FY27 SNAPSHOT ➢ Hospital business revenues grew 18.6% to INR 2,340 Cr versus INR 1,974 Cr in Q2FY26 ➢ Hospital Business Profit After Tax* stood at INR 281 Cr, up by 6.6%; while PAT margin was at 12.0% versus 13.4% in Q2FY26. ➢ Q2FY27 hospital business ARPP^ was at INR 2.10 Lacs vs INR 1.96 Lacs in Q2FY26, up 6.8% ➢ Occupancy for the quarter stood at 72% versus 71% in Q2FY26 ➢ The company’ [Showing first 8,000 characters — download PDF for full document]